Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

Raf Kinase Inhibitors

MAP kinase pathway consists of kinases such as Raf, MEK1/2, and ERK1/2, etc., that are critical for the proliferation and survival of tumor cells. Aberrant activation of RAF signaling is a frequent finding in human cancers. In addition to a role in controlling tumors with Ras mutations and activated growth factor receptors, Raf kinase inhibitors may harbor therapeutic potential in tumors carrying a BRAF oncogene. Numerous agents have been discovered to block Raf kinase, including many small molecules. These inhibitors prevent the expression of Raf protein, block Ras/Raf interaction, or obstruct its kinase activity. Several Raf kinase inhibitors are currently undergoing clinical evaluation. In 2013, the Raf family kinase inhibitor Sorafenib (BAY 43-9006) was approved by the FDA for the treatment of advanced renal carcinoma. BioVision is proud to offer Sorafenib as well as several other Raf kinase inhibitors for research.

24 Item(s)

per page

24 Item(s)

per page